<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310802</url>
  </required_header>
  <id_info>
    <org_study_id>14-OBE001-013</org_study_id>
    <nct_id>NCT02310802</nct_id>
  </id_info>
  <brief_title>OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI</brief_title>
  <acronym>IMPLANT</acronym>
  <official_title>A Phase 2, Double-blind, Dose-finding, Placebo-controlled Study to Assess the Safety and Efficacy of a Single Oral Administration of OBE001 to Improve Embryo Implantation Following IVF or ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ObsEva SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ObsEva SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the increase in clinical pregnancy rate
      after administration of a range of single oral doses of OBE001, an oral oxytocin antagonist,
      compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, dose-finding, randomised, parallel group, double-blind,
      placebo-controlled study investigating the efficacy and the safety of the oxytocin receptor
      antagonist OBE001 in 240 women undergoing embryo transfer following IVF or ICSI.

      The four-arm study (OBE001 dose 1, dose 2, dose 3, and placebo) design will allow evaluation
      of a possible dose-dependent pattern of action of OBE001 and, simultaneously, comparison of
      active compound with placebo with regard to both efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EFFICACY ENDPOINTS Percentage of women with an intra-uterine pregnancy with positive embryo heart-beat</measure>
    <time_frame>about 6 weeks post ET day</time_frame>
    <description>Percentage of women with an intra-uterine pregnancy with positive embryo heart-beat at about 6 weeks post ET day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EFFICACY ENDPOINTS Percentage of women with positive blood pregnancy test</measure>
    <time_frame>14 days post OPU day</time_frame>
    <description>Percentage of women with positive blood pregnancy test at 14 days post OPU day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFFICACY ENDPOINTS Percentage of women with an intra-uterine pregnancy with positive embryo heart-beat</measure>
    <time_frame>10 weeks post OPU day</time_frame>
    <description>Percentage of women with an intra-uterine pregnancy with positive embryo heart-beat at 10 weeks post OPU day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFFICACY ENDPOINTS The embryo-implantation rate</measure>
    <time_frame>6 weeks post ET day</time_frame>
    <description>The embryo-implantation rate defined as the number of intra-uterine embryos with positive heart-beat at 6 weeks post ET day divided by the number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFFICACY ENDPOINTS Change from baseline to the time of ET in the rate of uterine contractions</measure>
    <time_frame>at 3.5 hours after dose administration</time_frame>
    <description>Change from baseline to the time of ET in the rate of uterine contractions (UC/min).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>SAFETY ENDPOINTS Treatment emergent adverse events frequency and severity</measure>
    <time_frame>up to 10 weeks post OPU day</time_frame>
    <description>Treatment emergent adverse events frequency and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>SAFETY ENDPOINTS (Haematology and biochemistry assessments)</measure>
    <time_frame>14 days post OPU day</time_frame>
    <description>Haematology and biochemistry assessments at screening and at visit V3 (14 days post OPU day)</description>
  </other_outcome>
  <other_outcome>
    <measure>PHARMACOKINETIC ENDPOINTS Plasma levels of OBE001</measure>
    <time_frame>at 3.5 hours after dose administration</time_frame>
    <description>Plasma levels of OBE001</description>
  </other_outcome>
  <other_outcome>
    <measure>PHARMACOKINETIC-PHARMACODYNAMIC ENDPOINTS :Uterine contractions relationship to OBE001 plasma levels and pregnancy rate</measure>
    <time_frame>up 10 weeks post OPU day</time_frame>
    <description>Uterine contractions relationship to OBE001 plasma levels and pregnancy rate</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>OBE001 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OBE001 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OBE001 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OBE001 dose 1</intervention_name>
    <description>OBE001 dispersible tablets for single oral administration</description>
    <arm_group_label>OBE001 dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OBE001 dose 2</intervention_name>
    <description>OBE001 dispersible tablets for single oral administration</description>
    <arm_group_label>OBE001 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OBE001 dose 3</intervention_name>
    <description>OBE001 dispersible tablets for single oral administration</description>
    <arm_group_label>OBE001 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dispersible tablets for single oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          1. Women with medically indicated IVF or ICSI using her own oocytes.

          2. GnRH antagonist protocol, a single injection of hCG for triggering final follicular
             maturation and luteal phase support with vaginal micronized progesterone.

          3. Evidence of uterine contractions by transvaginal ultrasound at baseline.

        Key Exclusion Criteria

          1. Blastocyst stage or frozen-thaw transfers

          2. Clinically significant abnormalities in ECG, vital signs, physical examination or
             clinical laboratory results

          3. Severe endometriosis and/or adenomyosis or risk of ovarian hyper stimulation syndrome
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Director</last_name>
    <role>Study Director</role>
    <affiliation>ObsEva SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradev Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <disposition_first_submitted>September 21, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 21, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 28, 2017</disposition_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>ICSI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

